3-Carboxy-1-(4-sulfophenyl)-5-pyrazolone Sodium Salt

We are 3-Carboxy-1-(4-sulfophenyl)-5-pyrazolone Sodium Salt CAS:52126-51-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 3-Carboxy-1-(4-sulfophenyl)-5-pyrazolone Sodium Salt
CAS.NO:52126-51-9
Synonyms:5-Oxo-1-(4-sulfophenyl)-2-pyrazoline-3-carboxylic Acid Sodium Salt;Sodium 5-oxo-1-(4-sulfophenyl)-4H-pyrazole-3-carboxylate;3-Carboxy-1-(4-sulfophenyl)-5-pyrazolone SodiuM Salt
Molecular Formula:C10H7N2NaO6S
Molecular Weight: 306.22700
 
Physical and Chemical Properties:
Density:/
Boiling point:/
Melting point:/
Flash point:/
Index of Refraction:/
 
Specification:
Appearance:Light yellow crystalline powder
Purity:≥99.0%
 
Packing: 25kg drum
Storage:This product should be sealed in a cool dry place.
Application:Mainly used for organic synthesis C.I. Pigment Yellow 100; C.I. Acid Yellow 23 and Food Yellow 4; 5 and other varieties of coupling components.

3-Carboxy-1-(4-sulfophenyl)-5-pyrazolone Sodium Salt


Related News: Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California.Hept-6-enoic acid CAS:1119-60-4 In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.Dibenzo[b,d]thiophene-4,6-diboronic acid CAS:1266231-16-2 It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation.2-amino-5-nitrofenol CAS:121-88-0 As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.

Related Products
Product Name
ADENOSINE5′-MONOPHOSPHATESODIUMSALT View Details
Methyl 2-thiofuroate View Details
t-Butyl 4-bromobutanoate View Details
2,6-Difluorobenzyl bromide manufacturer L-Threonine Benzyl Ester Hydrochloride manufacturer 2,6-Dichloro-3-Iodopyridine manufacturer pentane-2-thiol manufacturer MOG (35-55) manufacturer